Venus Remedies Limited Fundamental Analysis
Venus Remedies Limited Fundamental Analysis
Venus Remedies Limited (VENUSREM.NS) shows moderate financial fundamentals with a PE ratio of 22.04, profit margin of 13.45%, and ROE of 17.28%. The company generates $7.6B in annual revenue with moderate year-over-year growth of 9.54%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 81.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze VENUSREM.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentVENUSREM.NS demonstrates superior asset utilization.
Valuation Score
ExcellentVENUSREM.NS trades at attractive valuation levels.
Growth Score
ExcellentVENUSREM.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentVENUSREM.NS maintains a strong and stable balance sheet.
Profitability Score
ModerateVENUSREM.NS maintains healthy but balanced margins.
Key Financial Metrics
Is VENUSREM.NS Expensive or Cheap?
P/E Ratio
VENUSREM.NS trades at 22.04 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, VENUSREM.NS's PEG of 0.17 indicates potential undervaluation.
Price to Book
The market values Venus Remedies Limited at 3.41 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 14.75 times EBITDA. This signals the market has high growth expectations.
How Well Does VENUSREM.NS Make Money?
Net Profit Margin
For every $100 in sales, Venus Remedies Limited keeps $13.45 as profit after all expenses.
Operating Margin
Core operations generate 15.22 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.28 in profit for every $100 of shareholder equity.
ROA
Venus Remedies Limited generates $12.04 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Venus Remedies Limited produces operating cash flow of $811.16M, showing steady but balanced cash generation.
Free Cash Flow
Venus Remedies Limited produces free cash flow of $682.25M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $51.04 in free cash annually.
FCF Yield
VENUSREM.NS converts 3.01% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
22.04
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.17
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.41
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.97
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.44
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.17
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
0.17
vs 25 benchmark
How VENUSREM.NS Stacks Against Its Sector Peers
| Metric | VENUSREM.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 22.04 | 28.99 | Better (Cheaper) |
| ROE | 17.28% | 698.00% | Weak |
| Net Margin | 13.45% | -52612.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.49 | Strong (Low Leverage) |
| Current Ratio | 2.44 | 4.42 | Strong Liquidity |
| ROA | 12.04% | -20544.00% (disorted) | Strong |
VENUSREM.NS outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Venus Remedies Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
77.67%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
518.39%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
8.99%
Industry Style: Defensive, Growth, Innovation
Growing